TLDR: "Discontinuation of GLP-1RA treatment leads to weight regain, regardless of lifestyle interventions, and should therefore be considered a chronic therapy to prevent weight regain and associated undesirable outcomes related to obesity." Key findings: After stopping liraglutide, patients regained ~2.2 kg After stopping semaglutide/tirzepatide, patients regained ~9.7 kg Weight regain was proportional to initial weight loss Lifestyle changes alone DID NOT prevent regain Implication: GLP-1 receptor agonists are not a short-term solution
Ozempic (injectable semaglutide) and Rybelsus ( oral semaglutide ) are FDA-approved for managing type 2 diabetes, along with healthy lifestyle changes
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily prescribed for the management of type 2 diabetes mellitus and, more recently, for weight management in adults with obesity or overweight with weight-related comorbidities
20 Debo acompaar el tratamiento con Wegovy/ Mounjaro con un seguimiento multidisciplinar
Gastrointestinal side effects associated with semaglutide typically occur more frequently during the initial weeks of treatment or following dose escalation